Albert David Limited (ALBERTDAVD.NS)
INR 825.75
(-1.8%)
INR 825.75
(-1.8%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.15 Billion INR | 2.85% |
| 2022 | 1.11 Billion INR | -9.36% |
| 2021 | 1.23 Billion INR | 27.16% |
| 2020 | 970.19 Million INR | -0.41% |
| 2019 | 974.18 Million INR | 14.69% |
| 2018 | 849.44 Million INR | -17.72% |
| 2017 | 1.03 Billion INR | 5.78% |
| 2016 | 975.92 Million INR | 12.16% |
| 2015 | 870.14 Million INR | -13.53% |
| 2014 | 1 Billion INR | -6.53% |
| 2013 | 1.07 Billion INR | -16.21% |
| 2012 | 1.28 Billion INR | 0.95% |
| 2011 | 1.27 Billion INR | 33.32% |
| 2010 | 954.67 Million INR | -21.71% |
| 2009 | 1.21 Billion INR | 15.46% |
| 2008 | 1.05 Billion INR | 6.61% |
| 2007 | 990.58 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -3.82 Billion INR | -433.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 1.04 Billion INR | 0.0% |
| 2023 Q4 | 1.15 Billion INR | 0.0% |
| 2023 FY | 1.15 Billion INR | 2.85% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q4 | 1.11 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 1.11 Billion INR | -9.36% |
| 2022 Q2 | 1.18 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 1.26 Billion INR | 0.0% |
| 2021 Q4 | 1.23 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 1.23 Billion INR | 27.16% |
| 2020 Q2 | 997.83 Million INR | 0.0% |
| 2020 Q4 | 970.19 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 970.19 Million INR | -0.41% |
| 2019 Q2 | 994.82 Million INR | 0.0% |
| 2019 FY | 974.18 Million INR | 14.69% |
| 2019 Q4 | 974.18 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q4 | 849.44 Million INR | 0.0% |
| 2018 FY | 849.44 Million INR | -17.72% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q2 | 907.85 Million INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q4 | 1.03 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 FY | 1.03 Billion INR | 5.78% |
| 2017 Q2 | 921.22 Million INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 975.92 Million INR | 12.16% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q4 | 975.92 Million INR | 0.0% |
| 2016 Q2 | 916.06 Million INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q4 | 870.14 Million INR | 0.0% |
| 2015 FY | 870.14 Million INR | -13.53% |
| 2015 Q2 | 967.89 Million INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 980.38 Million INR | 0.0% |
| 2014 FY | 1 Billion INR | -6.53% |
| 2014 Q4 | 1 Billion INR | 0.0% |
| 2013 Q2 | 1.32 Billion INR | 0.0% |
| 2013 Q4 | 1.07 Billion INR | 0.0% |
| 2013 FY | 1.07 Billion INR | -16.21% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2012 FY | 1.28 Billion INR | 0.95% |
| 2012 Q4 | 1.28 Billion INR | 0.0% |
| 2012 Q2 | 1.25 Billion INR | 0.0% |
| 2011 FY | 1.27 Billion INR | 33.32% |
| 2011 Q4 | 1.27 Billion INR | 0.0% |
| 2010 FY | 954.67 Million INR | -21.71% |
| 2009 FY | 1.21 Billion INR | 15.46% |
| 2008 FY | 1.05 Billion INR | 6.61% |
| 2007 FY | 990.58 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Lupin Limited | 96.23 Billion INR | 98.805% |
| Sigachi Industries Limited | 2.53 Billion INR | 54.564% |
| Innova Captab Limited | 4.89 Billion INR | 76.528% |
| Ind-Swift Limited | 13.45 Billion INR | 91.451% |
| Bajaj HealthCare Limited | 4.86 Billion INR | 76.373% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 99.244% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | 91.838% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | 68.586% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | 41.805% |
| Morepen Laboratories Limited | 4.45 Billion INR | 74.212% |
| Sequent Scientific Limited | 8.27 Billion INR | 86.1% |
| Wanbury Limited | 3.15 Billion INR | 63.553% |
| Laurus Labs Limited | 42.71 Billion INR | 97.307% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 89.748% |
| Aarti Drugs Limited | 11.5 Billion INR | 90.003% |
| Gufic Biosciences Limited | 5.59 Billion INR | 79.462% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | 77.801% |
| Alembic Limited | 1.43 Billion INR | 19.691% |
| Hikal Limited | 12.99 Billion INR | 91.15% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 92.933% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 98.234% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 81.828% |
| Themis Medicare Limited | 1.88 Billion INR | 39.068% |
| RPG Life Sciences Limited | 1.38 Billion INR | 16.671% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -46.73% |
| Vaishali Pharma Limited | 371.16 Million INR | -209.865% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 86.061% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -287.554% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 98.123% |
| FDC Limited | 3.7 Billion INR | 68.993% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -78.62% |
| Eris Lifesciences Limited | 38.26 Billion INR | 96.995% |
| Windlas Biotech Limited | 1.76 Billion INR | 34.753% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.373% |
| Venus Remedies Limited | 1.39 Billion INR | 17.425% |
| ZIM Laboratories Limited | 2.08 Billion INR | 44.727% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -7.032% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -619.756% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | 67.192% |
| Shilpa Medicare Limited | 12.93 Billion INR | 91.107% |
| Orchid Pharma Limited | 3.84 Billion INR | 70.081% |
| Hester Biosciences Limited | 3.59 Billion INR | 68.006% |
| Sakar Healthcare Limited | 1.26 Billion INR | 8.959% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | 43.462% |
| Procter & Gamble Health Limited | 2.56 Billion INR | 55.095% |
| Divi's Laboratories Limited | 18.99 Billion INR | 93.944% |
| Mankind Pharma Limited | 23.87 Billion INR | 95.183% |
| Neuland Laboratories Limited | 5.49 Billion INR | 79.084% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 89.259% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 98.398% |
| Wockhardt Limited | 39.87 Billion INR | 97.115% |
| Bal Pharma Limited | 2.51 Billion INR | 54.202% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 98.925% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | 45.463% |
| Alkem Laboratories Limited | 48.6 Billion INR | 97.634% |
| Valiant Laboratories Limited | 1.05 Billion INR | -8.679% |
| Ajanta Pharma Limited | 10.71 Billion INR | 89.262% |
| Unichem Laboratories Limited | 8.06 Billion INR | 85.747% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -76.321% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -298.237% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | 33.218% |
| Granules India Limited | 22.95 Billion INR | 94.99% |
| Medicamen Biotech Limited | 940.36 Million INR | -22.304% |
| Medico Remedies Limited | 438.24 Million INR | -162.435% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | 49.765% |
| Ipca Laboratories Limited | 33.74 Billion INR | 96.592% |
| Brooks Laboratories Limited | 248.6 Million INR | -362.631% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | 1.296% |
| Piramal Enterprises Limited | 560.47 Billion INR | 99.795% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 98.598% |
| NATCO Pharma Limited | 10.53 Billion INR | 89.08% |
| Suven Life Sciences Limited | 148.62 Million INR | -673.851% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 61.327% |
| Strides Pharma Science Limited | 37.68 Billion INR | 96.948% |
| Indoco Remedies Limited | 10.34 Billion INR | 88.88% |
| Alpa Laboratories Limited | 307.12 Million INR | -274.478% |
| Lasa Supergenerics Limited | 541.92 Million INR | -112.226% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 70.456% |